DUBLIN–(BUSINESS WIRE)–The “Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union Training Course (Mar 5th – Mar 6th, 2026)” training has been addedDUBLIN–(BUSINESS WIRE)–The “Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union Training Course (Mar 5th – Mar 6th, 2026)” training has been added

Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union Training Course (Online Event: Mar 5th – Mar 6th, 2026) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union Training Course (Mar 5th – Mar 6th, 2026)” training has been added to ResearchAndMarkets.com’s offering.

This interactive course will guide you through national procedures as well as explore the implications of and updates on the Eurasian Union regulation.

The pharmaceutical markets in Russia, the Eurasian Union and the CIS are of growing commercial importance and companies looking to take advantage of the opportunities available need to be fully up to date with the evolving regulatory landscape for human pharmaceuticals, including the potential for market access offered by the latest legislation.

The focus of the programme is to offer practical advice in developing your regulatory strategy for product approval in these countries and you will get the full benefit of our trainer’s experience and expertise in the region.

Benefits of attending:

  • Understand the competitive landscape of the growing markets in the CIS region
  • Discover the essential information on the latest regulations and registration procedures in the Eurasian Customs Union
  • Discuss national requirements and guidance for drug approval in the core CIS markets of Russia, Kazakhstan, Belarus, Ukraine and Azerbaijan
  • Develop your CIS regional submission plan and place it within your global regulatory strategy
  • Gain practical advice from an industry expert working in the CIS region

Why you should attend

Attending this programme will:

  • Give you the full background to the CIS pharmaceutical market
  • Ensure that you understand all the implications of the latest regulations which will affect how you do business in the Eurasian Economic Union (EAEU)
  • Help clarify the document requirements and timelines of national procedures and EAEU registration procedures
  • Update you on the national regulations in Russia, Belarus, Kazakhstan, Ukraine and other CIS countries

Who Should Attend:

This seminar will be of particular interest to all those who need to learn about successful marketing authorisation applications and regulatory compliance in this region. The seminar will be useful either as an introductory or refresher course.

Certifications:

  • CPD: 12 hours for your records
  • Certificate of completion

Key Topics Covered:

Day 1

CIS – regional regulatory overview

  • CIS and Russia Market Overview
  • Market protection policies
  • CIS and Russia in regional and international Regulatory Harmonisation

Common regional requirements in CIS

  • Administrative data, translations, normative documents, samples, labelling, etc

Eurasian economic area

  • Countries current members of EAEU and EAEU Official bodies
  • History of EUAE, scope of products, available experience
  • Terms of transition period for medicines

Eurasian Regulations for Medicines

  • Overview of EAEU regulatory framework
  • Registration Procedures and Application Process
  • EAEU submission documents and data requirements
  • GMP inspections
  • PhV requirements

Day 2

Registration of Medicine in Russia

  • Regulatory authorities in Russia
  • Key regulations governing the registration process
  • Clinical trials

National Regulatory Procedures in Russia

  • Application dossier and data requirements
  • Post approval life cycle maintenance applications
  • Safety reporting and market surveillance
  • Price and reimbursement
  • Patent data protection

Registration in other EAEU countries

  • Kazakhstan, Belarus, Armenia, Kirgizstan

Registration in other CIS countries

  • EU sphere of influence: Ukraine, Moldova, Georgia
  • National procedures: Azerbaijan, Uzbekistan, Tajikistan, Turkmenistan

Workshop – CIS Regional Regulatory Strategy

Speakers:

Anna Harrington-Morozova

Scientific and Regulatory Director

Regem Consulting Ltd

Anna Harrington-Morozova is a regulatory, drug development and external relations professional with over 20 years’ experience gained in regulatory authority, academia, clinical and industry environment. Anna graduated in Russia as a pharmacist. After working in the Russian Ministry of Health and the Clinical Pharmacology Department of Moscow Medical University Anna held regulatory and external relation positions in the pharmaceutical industry and CROs in Russia and the UK, including senior regulatory affairs posts in GSK, EISAI, ICON and PRA. Anna currently acts as a Scientific and Regulatory Director at Regem Consulting Ltd – a regulatory and drug development consultancy with a focus on global regulatory and drug development strategies, advocacy and registrations in emerging markets.

For more information about this training visit https://www.researchandmarkets.com/r/rthrb0

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Semler Scientific founder: Special shareholders' meeting approving the proposed merger with Strive will be held on January 13.

Semler Scientific founder: Special shareholders' meeting approving the proposed merger with Strive will be held on January 13.

PANews reported on December 30th that Eric Semler, founder of the US-listed company Semler Scientific, issued a statement urging all shareholders to vote in favor
Share
PANews2025/12/30 08:23
Fed’s 25bps cut sparks Bitcoin repricing: October breakout ahead?

Fed’s 25bps cut sparks Bitcoin repricing: October breakout ahead?

The post Fed’s 25bps cut sparks Bitcoin repricing: October breakout ahead? appeared on BitcoinEthereumNews.com. Journalist Posted: September 18, 2025 Key Takeaways How is BTC reacting to the Fed’s rate cut? Bitcoin is grinding +0.72%, range-bound, with flows measured and a potential long squeeze in play. What’s setting up Bitcoin for year-end? Dovish Fed signals, seasonal tailwinds, and aligned macro flows keep BTC primed for a potential ATH. No parabolic moves, just Bitcoin [BTC] grinding +0.72% intraday as the FOMC delivers its first 25 bps cut of 2025. The tape is cautious, with range-bound action signaling traders are sitting tight. What’s the takeaway? Market participants are still sizing up Q4, with Fed Chair Powell’s mixed signals on future rate cuts keeping flows measured, as Matt Mena, Crypto Research Strategist at 21Shares, told AMBCrypto. “The cut itself was widely priced in – what mattered more was the Fed’s updated dot plot. Futures markets had been discounting only a 50% chance of 4–5 cuts through the end of next year.” He added, “While today’s 25bps cut provided the spark, it is the path implied by the dots – more than the cut itself – that may set the stage for Bitcoin to challenge new highs into year-end.” Fed’s dot plot shapes BTC’s long-term positioning Bitcoin traders are leaning on the Fed’s dot plot to size up positioning.  According to the latest projections, the Fed is signaling two more 25bps cuts by year-end, pushing the target range down to 3.50%–3.75% from 4.00%–4.25%. In short, Bitcoin’s long-term positioning remains dovish. Powell’s inflation caution capped the short-term squeeze, keeping the tape range-bound. Yet the dot plot shows most Fed officials leaning toward two more cuts, keeping BTC positioned to grind toward new highs by year-end. “The dots leaned more dovish, signaling the Fed is open to accelerating the pace of easing if conditions demand it. That repricing risk is now…
Share
BitcoinEthereumNews2025/09/18 22:27
Solana and Ethereum Stablecoins Gain Traction in Europe Amid Regulatory Scrutiny

Solana and Ethereum Stablecoins Gain Traction in Europe Amid Regulatory Scrutiny

The post Solana and Ethereum Stablecoins Gain Traction in Europe Amid Regulatory Scrutiny appeared on BitcoinEthereumNews.com. Ethereum and Solana stablecoins have
Share
BitcoinEthereumNews2025/12/30 08:15